KYMOS Pharma Services inaugurated its new headquarters, with 1,500 square meters in the Vallès Technology Park located in Barcelona, Spain. The new headquarters, with office and laboratory space, has been fitted with latest-generation equipment, including two technology platforms for mass spectrometry and immunology. The company has invested a total of €2 million.

“These new laboratories will allow us to expand our capacity and the R&D and quality control services we offer the biopharmaceutical industry, and to continue with our international growth plan by committing to the latest-generation biologic products market,” said Joan Puig de Dou, strategic general manager and partner in the company. “The services we offer make research costs variable, make it possible to access innovative technology and speed up time to market.”

KYMOS has GLP (Good Laboratory Practices) and GMP (Good Manufacturing Practices) certification and is an authorized pharmaceutical laboratory for the analysis and import of medicines.

KYMOS carries out its activity in both the more traditional area of small molecules from chemical synthesis and that of biological products obtained through biotechnology processes—proteins, monoclonal antibodies, vaccines, etc.—an area the company moved into in 2012 after reaching a strategic agreement with French multinational corporation Ipsen.

Currently 40% of the company’s activity comes from the international market, mainly France, Italy, Switzerland and Portugal, although they also have clients in other countries with high potential for growth like the United States, Japan, Latin America and India. The company expects to post 12% growth for 2015.